Alan Minsk and Brian Teras Discuss FDA Regulatory Considerations for Mergers and Acquisitions on FDA Watch Podcast

AGG Food & Drug chair Alan Minsk and Corporate partner Brian Teras joined the FDA Watch Podcast for the final installment of its Legal, Regulatory & Compliance Series.

During the episode, “FDA Legal, Regulatory & Compliance Issues, Part 4: Mergers & Acquisitions,” Alan and Brian discuss current M&A trends affecting FDA-regulated companies, including how FDA’s regulatory approach can influence corporate transactions and dealmaking activity.

The conversation also explores FDA’s Transparency Roadmap and its implications for M&A, common mistakes buyers and sellers make when evaluating potential transactions, and emerging regulatory developments that could affect future deals.

Drawing on their experience advising life sciences companies on regulatory compliance and corporate transactions, Alan and Brian give advice to businesses and investors seeking to identify potential risks, conduct effective due diligence, and make informed decisions throughout the M&A process.

To listen to the full episode, please click here.